Work

Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5526

Authors: Naveen Pemmaraju, Ellen Ritchie, John Mascarenhas, Salman Fazal, Erin Crowgey, TaeHyung (Simon) Kim, J.E. Hamer-Maansson, Tricia Kalafut, Evan Braunstein, Abdulraheem Yacoub

Institutions: The University of Texas MD Anderson Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai, Incyte (United States), University of Kansas Medical Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417016563

Cites:

Cited by:

Related to: